United Therapeutics is making headway in unlocking a new lung disease market for its drug Tyvaso (treprostinil) with a ...

If approved, Tyvaso could redefine SoC for idiopathic pulmonary fibrosis (IPF), a GlobalData analyst tells Clinical Trials ...

(Reuters) -Shares of United Therapeutics surged 37% to an all-time high on Tuesday after its drug Tyvaso significantly improved lung function in patients with a progressive lung condition in a ...

Patients diagnosed with idiopathic pulmonary fibrosis (IPF) and other rare respiratory diseases often face a poor prognosis and limited treatment options. Although the two approved IPF treatments slow ...

Shares of United Therapeutics jumped nearly 40% on Tuesday’s opening trade after the company reported its inhaled lung ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

In a study published in Aging on Aug. 8, 2025, researchers at Insilico Medicine unveiled AI-powered models that uncover shared biological pathways between IPF and the aging process, pointing to novel ...

(Reuters) -Shares of United Therapeutics surged over 42% in premarket trading on Tuesday after its lung disease treatment, treprostinil, met the main goal in a late stage study. The inhaled drug, ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic interstitial lung disease characterized by progressive scarring of lung tissue, which impairs oxygen exchange and leads to breathing difficulties.

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterised by the accumulation of scar tissue in the ...

Woman Who Watched 5 Family Members Die From Rare Lung Disease Searches for Answers: 'It Was Torment' Idiopathic pulmonary fibrosis causes patients to feel as if they were breathing through a ...